Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00010218 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: karenitecin

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]